pancreatic cancer
Immunovia, JW BioScience Ink Licensing Agreement for Early Pancreatic Cancer Detection Biomarkers
Immunovia said that it has secured intellectual property rights to the biomarkers, which are part of the diagnostic signature for its Immray PanCan-d blood test.
Immunovia Receives Massachusetts Approval to Begin Testing of Patients for Pancreatic Cancer
The firm said its laboratory developed test, which recognizes biomarker signatures in the blood, can detect pancreatic cancer early when surgical resection is possible.
Bluestar Genomics Raises $70M in Series C Funding Round
The San Diego-based early cancer detection firm has also appointed Felix Fang and Craig Venter to its scientific advisory board.
The firm said that recent validation studies have shown that a positive result with its PanCan-d microarray test could accelerate diagnosis for high-risk individuals.
Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker
Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management.